Loading...
Header Logo
Keywords
Last Name
Institution

JIANJUN GAO

TitleAssistant Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 Oct 29; 116(44):22246-22251. PMID: 31611368.
      View in: PubMed
    2. Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812. PMID: 31466995.
      View in: PubMed
    3. Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 Oct 20; 37(30):2738-2745. PMID: 31163011.
      View in: PubMed
    4. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 May 07; 27(6):1781-1793.e4. PMID: 31067463.
      View in: PubMed
    5. Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis. 2019 01 10; 25(2):385-393. PMID: 30169584.
      View in: PubMed
    6. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2019 Jan; 25(1):188. PMID: 30479380.
      View in: PubMed
    7. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808. PMID: 30420754.
      View in: PubMed
    8. Tabayoyong W, Gao J. The emerging role of immunotherapy in advanced urothelial cancers. Curr Opin Oncol. 2018 05; 30(3):172-180. PMID: 29553950.
      View in: PubMed
    9. Tabayoyong W, Li R, Gao J, Kamat A. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urol Clin North Am. 2018 May; 45(2):155-167. PMID: 29650132.
      View in: PubMed
    10. Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017 09; 9(10):781-784. PMID: 28877627.
      View in: PubMed
    11. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097. PMID: 28733428.
      View in: PubMed
    12. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412.
      View in: PubMed
    13. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149.
      View in: PubMed
    14. Kim C, Gao J, Shannon VR, Siefker-Radtke A. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep. 2016 Oct 26; 2016. PMID: 27797838.
      View in: PubMed
    15. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924. PMID: 27698113.
      View in: PubMed
    16. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9. PMID: 27667683.
      View in: PubMed
    17. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335. PMID: 27498556.
      View in: PubMed
    18. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016; 4:36. PMID: 27330809.
      View in: PubMed
    19. Campbell MT, Siefker-Radtke AO, Gao J. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Cancer J. 2016 Mar-Apr; 22(2):96-100. PMID: 27111904.
      View in: PubMed
    20. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29. PMID: 26014097.
      View in: PubMed
    21. Siefker-Radtke AO, Gao J. Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol. 2015 Jan; 16(1):9-10. PMID: 25498220.
      View in: PubMed
    22. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014 Nov 10; 349:g4797. PMID: 25385470.
      View in: PubMed
    23. Gou HF, Li X, Qiu M, Cheng K, Li LH, Dong H, Chen Y, Tang Y, Gao F, Zhao F, Men HT, Ge J, Su JM, Xu F, Bi F, Gao JJ, Liu JY. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One. 2013; 8(4):e62175. PMID: 23637996.
      View in: PubMed
    24. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90. PMID: 23092383.
      View in: PubMed
    25. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol. 2013 Feb; 34(2):90-8. PMID: 23031830.
      View in: PubMed
    26. Gao JJ, Shen J, Kolbert C, Raghavakaimal S, Papasian CJ, Qureshi AA, Vogel SN, Morrison DC, Qureshi N. The proteasome regulates bacterial CpG DNA-induced signaling pathways in murine macrophages. Shock. 2010 Oct; 34(4):390-401. PMID: 20160661.
      View in: PubMed
    27. Gao JJ, Maricque BB, Morse MD, Huang W, McNeel DG. Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol. 2010 Nov 20; 28(33):e680-3. PMID: 20805455.
      View in: PubMed
    28. Shen J, Gao JJ, Zhang G, Tan X, Morrison DC, Papasian C, Vogel SN, Qureshi N. Proteasome-mediated regulation of CpG DNA- and peptidoglycan-induced cytokines, inflammatory genes, and mitogen-activated protein kinase activation. Shock. 2006 Jun; 25(6):594-9. PMID: 16721267.
      View in: PubMed
    29. Lei MG, Gao JJ, Morrison DC, Qureshi N. Pathogenesis of sepsis: current concepts and emerging therapies. Mo Med. 2003 Sep-Oct; 100(5):524-9. PMID: 14601445.
      View in: PubMed
    30. Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, Follettie MT. Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages. J Endotoxin Res. 2003; 9(4):237-43. PMID: 12935354.
      View in: PubMed
    31. Papasian CJ, Silverstein R, Gao JJ, Bamberger DM, Morrison DC. Anomalous role of tumor necrosis factor alpha in experimental enterococcal infection. Infect Immun. 2002 Dec; 70(12):6628-37. PMID: 12438335.
      View in: PubMed
    32. Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, Follettie MT. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol. 2002 Dec; 72(6):1234-45. PMID: 12488506.
      View in: PubMed
    33. Gao JJ, Xue Q, Papasian CJ, Morrison DC. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol. 2001 Jun 01; 166(11):6855-60. PMID: 11359845.
      View in: PubMed
    34. Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KN. Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res. 2001 Apr; 21(4):231-40. PMID: 11359654.
      View in: PubMed
    35. Gao JJ, Filla MB, Lorsbach RB, Pace JL, Crespo A, Russell SW, Murphy WJ. Prolonged exposure of mouse macrophages to IFN-beta suppresses transcription of the inducible nitric oxide synthase gene: altered availability of transcription factor Stat1alpha. Eur J Immunol. 2000 Jun; 30(6):1551-61. PMID: 10898490.
      View in: PubMed
    36. Chu W, Gao J, Murphy WJ, Hunt JS. A candidate interferon-gamma activated site (GAS element) in the HLA-G promoter does not bind nuclear proteins. Hum Immunol. 1999 Nov; 60(11):1113-8. PMID: 10600009.
      View in: PubMed
    37. Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R, Morrison DC. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol. 1999 Oct 15; 163(8):4095-9. PMID: 10510342.
      View in: PubMed
    38. Gao JJ, Filla MB, Fultz MJ, Vogel SN, Russell SW, Murphy WJ. Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J Immunol. 1998 Nov 01; 161(9):4803-10. PMID: 9794412.
      View in: PubMed
    39. Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJ. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem. 1997 Jan 10; 272(2):1226-30. PMID: 8995425.
      View in: PubMed
    40. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 4.
    41. The state of immune checkpoint inhibition in urothelial carcinoma current evidence and future areas of exploration. Cancer Journal (United States). 22:96-100.
    42. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167:397-404.e9.
    43. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab. Oncogene.
    44. LPS stimulates statla phosphorylation in mouse macrophages without autocrine feedback by interferon-γ. FASEB Journal. 10.
    45. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.
    46. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    47. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Reports. 2016.
    48. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. 113:11919-11924.
    49. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7.
    GAO's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description